PCSK-9 inhibitors for hyperlipidemia a review of the comparative clinical effectiveness
Alirocumab and evolocumab are expensive drugs (annual cost per patient > Can
Main Authors: | , , |
---|---|
Corporate Author: | |
Format: | eBook |
Language: | English |
Published: |
Ottawa
CADTH
2017, June 6, 2017
|
Series: | CADTH rapid response report: summary with critical appraisal
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | Alirocumab and evolocumab are expensive drugs (annual cost per patient > Can |
---|---|
Physical Description: | 1 PDF file (21 pages) illustrations |